Metfogamma 850

Quick links

Choose a section

Quick links to important sections

Advertisements

Metfogamma 850

Selected form

Advertisements
Advertisements
Advertisements

Overview of Metfogamma 850

Property Description
Active ingredient Metformin Hydrochloride (850 mg)
Form Film-coated tablet
Pharmacological class Biguanide (Antihyperglycemic agent)
Common use Supporting blood glucose control
Origin Synthetic derivative of guanidine

1. Defining Metfogamma 850: An Antihyperglycemic Biguanide

Metfogamma 850 is a specific, prescription-only pharmaceutical product containing the singular active compound, Metformin Hydrochloride. It is firmly classified within the biguanide pharmacological class, a category of antihyperglycemic agents recognized for managing elevated blood sugar levels. This core ingredient is a synthetic derivative of guanidine, a naturally occurring substance. Metformin Hydrochloride is structurally distinct from other classes of oral agents, such as sulfonylureas, and is clinically established as a foundational strength for primary glycemic intervention in adults.

2. Composition and Form: The Metformin 850 mg Tablet

The medicine is supplied as a film-coated tablet intended for oral administration. Each tablet unit delivers precisely 850 milligrams of Metformin Hydrochloride, ensuring consistent dosing. The film coating is a design element intended to enhance the ease of swallowing and protect the active substance. The product adheres to rigorous quality standards for manufacturing and formulation, which ensures the solid matrix releases the Metformin effectively for systemic absorption.

3. General Purpose: Targeting High Blood Sugar

The fundamental purpose of Metfogamma 850 is to help the body achieve and sustain effective glycemic control by working directly to reduce elevated blood glucose levels. The drug's primary role involves suppressing the excessive production of glucose by the liver and enhancing the body's natural sensitivity to insulin. Its use is recognized in clinical practice as a primary step to improve overall glucose metabolism.

Regulatory References

  1. Metformin-Associated Lactic Acidosis (MALA) - StatPearls
Advertisements

What side effects are possible with Metfogamma 850?

The official regulatory safety documentation for Metfogamma 850 (metformin hydrochloride) identifies the primary risk as Lactic Acidosis. This is a rare, but serious and potentially fatal metabolic complication, listed with a Boxed Warning by the FDA. Risk factors for this condition include significant renal impairment (kidney disease), conditions leading to tissue oxygen deprivation (hypoxia, such as acute congestive heart failure), excess alcohol intake, and age 65 years or greater.

Adverse Reactions

The most common adverse reactions, typically observed during treatment initiation, involve the gastrointestinal system and include diarrhea, nausea, vomiting, flatulence, and abdominal discomfort.

Classification System-Organ Class Involved Key Adverse Reactions
Very Common / Common Gastrointestinal disorders Diarrhea, Nausea, Vomiting, Abdominal pain
Rare Metabolism and nutrition disorders Lactic Acidosis
Safety Concern Metabolism and nutrition disorders Decreased Vitamin B12 levels

Safety Restrictions and Monitoring

Metformin is contraindicated in patients with severe renal impairment (eGFR below 30 mL/minute/1.73 m^2) and in cases of metabolic acidosis. Treatment must be temporarily discontinued before or at the time of an iodinated contrast imaging procedure and certain surgical procedures in specified high-risk patients. Renal function (eGFR) must be assessed before starting therapy and at least annually thereafter. Patients are cautioned against excessive alcohol consumption due to the potentiated risk of lactic acidosis.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The most severe, life-threatening manifestation of Metformin overdose documented in regulatory prescribing information is Metformin-associated Lactic Acidosis (MALA). Lactic Acidosis is recognized as a medical emergency characterized by specific laboratory findings, notably elevated blood lactate levels and a decreased blood pH (anion gap acidosis).

Nonspecific symptoms that may signal the onset of this severe complication, and which trigger the need for immediate action, include malaise, myalgias (muscle pain), somnolence (unusual drowsiness), and respiratory distress (difficulty breathing). Hypotension and an altered level of consciousness are also documented clinical signs of severe toxicity.


Regulatory Mandates for Emergency Response

Mandated Action Regulatory Statement Summary
Immediate Help-Seeking Individuals must seek immediate emergency medical treatment or call the Poison Help line upon the first sign of these nonspecific symptoms.
Drug Discontinuation The medication must be immediately discontinued if Lactic Acidosis is suspected or confirmed.
Treatment Procedure Prompt hemodialysis is the procedure formally recommended for managing overdose, as it effectively removes Metformin from the blood. No specific antidote is known.
Population Risk Patients with pre-existing renal impairment, hepatic impairment, or advanced age face significantly higher risk for this complication.

The official overdose structure requires the immediate discontinuation of the drug followed by urgent medical assessment and supportive care, focusing on prompt removal of the accumulated drug.

Advertisements

Therapeutic Uses of Metfogamma 850

The fundamental purpose of Metfogamma 850 is to provide therapeutic support for conditions characterized by systemic imbalance and chronic glucose dysregulation, generally contributing to significant patient benefits in long-term disease management and risk reduction. The medication is primarily used to control the amount of glucose in the blood.

The core therapeutic domains include managing Type 2 Diabetes Mellitus (T2DM), addressing prediabetes (high-risk metabolic states) for proactive risk modification, and specialized support for metabolic abnormalities such as those found in Polycystic Ovary Syndrome (PCOS) and Gestational Diabetes Mellitus (GDM). It is commonly used to help with symptoms related to systemic imbalance, specifically chronic hyperglycemia (persistent high blood sugar levels).

“provides support that helps ease the overall symptom burden and assists with maintaining functional stability.”

In clinical practice, Metfogamma 850 is commonly used as the initial pharmacological step when diet and exercise alone are insufficient, or as part of combination therapy. The medication may help patients cope more steadily with symptom fluctuations by supporting reduced risk of serious cardiovascular events.

Quick Fact: Management of Metabolic Symptoms
It assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms associated with long-term glycemic management.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Metfogamma 850 (metformin) is authorized for use in adults and children from 10 years of age and adolescents who have Type 2 Diabetes Mellitus. Eligibility is strictly defined by regulatory bodies to manage the risk of lactic acidosis, a rare but serious complication.

Eligibility Scope

Classification Official Regulatory Statements
Populations Allowed Adults, and pediatric patients ge 10 years old (as monotherapy or in combination with insulin) [FDA/EMA].
Populations Contraindicated Severe Renal Impairment (estimated GFR < 30 mL/min/1.73m^2); Hepatic Insufficiency; Acute Metabolic Acidosis (including diabetic ketoacidosis); and Acute Conditions that may cause tissue hypoxia (e.g., decompensated heart failure) [EMA SmPC].
Restricted or Conditional Use Use in moderate renal impairment (eGFR 30 –59 mL/min/1.73m^2) requires dose reduction and frequent monitoring of renal function. The medicine must be temporarily discontinued before or during procedures involving iodinated contrast media or major surgery [FDA DailyMed].
Pregnancy/Lactation Not recommended during pregnancy (insulin is preferred) or while breastfeeding/lactating [NAFDAC SmPC].

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility by establishing absolute contraindications tied to severe organ dysfunction (renal and hepatic) and unstable clinical states (acidosis, hypoxia) to mitigate the risk of complications. For all other approved T2DM populations (adults and children ge 10 with adequate organ function), use is permitted, while specific physiological states or procedural requirements trigger explicit restrictions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metfogamma 850 (Metformin Hydrochloride) interacts with several medicinal products and substances, primarily due to effects on its renal clearance or impacts on lactate and glucose metabolism, as documented in regulatory prescribing information.


Contraindicated Combinations

Intravascular administration of iodinated contrast agents is a formally prohibited combination because it may acutely alter kidney function, increasing the risk of lactic acidosis. Acute and excessive alcohol intoxication is also contraindicated, especially with fasting or malnutrition, as it potentiates the effect on lactate metabolism.


Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with inhibitors of the Organic Cation Transporter 2 (OCT2), such as Cimetidine, Ranolazine, or Dolutegravir, decreases Metformin’s renal elimination. This mechanism increases the systemic plasma concentration of Metformin, raising the potential for accumulation.

When combined with other glucose-lowering agents, including insulin secretagogues or insulin, there is an increased risk of hypoglycemia. Additionally, drugs that can acutely impair kidney function, such as some NSAIDs, ACE inhibitors, and diuretics, may heighten the risk of lactic acidosis. Metformin may also cause a reduction in serum Vitamin B12 levels.

Food decreases the extent of Metformin absorption, resulting in a 40% lower mean peak plasma concentration ( C max) and a 25% lower Area Under the Curve (AUC).


Administration Restrictions

Metfogamma 850 must be temporarily discontinued prior to or at the time of any imaging procedure using iodinated contrast media and must not be reinstituted until at least 48 hours after the procedure, provided that kidney function has been re-evaluated and found to be normal. Temporary withholding is also required for certain surgical procedures.

Advertisements

Mechanism of Action

Mechanism of Action: Modulating Glucose Homeostasis

Metfogamma 850 (Metformin) influences systems governing glucose concentration primarily through dual action on the liver and peripheral tissues. The mechanism begins in the liver, where the drug is concentrated via the OCT1 transporter.

Metformin mildly inhibits the Mitochondrial Respiratory Chain Complex I, shifting the hepatocyte's energy balance and leading to the activation of the AMPK enzyme. This enzyme activation shuts down the processes required for gluconeogenesis (glucose creation), resulting in a suppression of glucose output into the bloodstream.

Beyond the liver, the mechanism contributes to an enhancement of systemic insulin sensitivity. By activating AMPK in muscle and fat tissues, the drug alters the cell’s machinery for taking up glucose from the circulation, facilitating a greater rate of glucose clearance into peripheral cells. The function of this mechanism is physiologically constrained when renal function is impaired, as the drug requires renal elimination.

Advertisements

Dosage and Administration Information

Metfogamma 850, an immediate-release Metformin Hydrochloride tablet, is administered exclusively via the oral route. The administration is characterized by a gradual initiation and a continuous, long-term pattern of use. The treatment protocol mandates that the tablets be taken in divided doses as part of a structured regimen.


Administration Regimens

The standard regimen begins with a low starting dose, typically 500 mg twice daily or 850 mg once daily. The dose is designed to be increased slowly, generally in increments of 500 mg weekly or 850 mg every two weeks. The usual maintenance range is 1500 mg to 2000 mg daily, and the maximum recommended adult dose is 2550 mg per day, always administered in divided doses.

To enhance gastrointestinal tolerability, the tablets must be taken with meals or immediately following them. The tablets must be swallowed whole with water and should not be crushed, cut, or chewed. For pediatric patients (ages 10 and older), the starting regimen is 500 mg twice daily, with a maximum dose of 2000 mg per day.


Contextual Constraints

Usage is subject to constraints related to renal function. The drug must not be initiated or continued if the estimated Glomerular Filtration Rate (eGFR) falls below specific thresholds, such as 30 mL/min/1.73 m^2. Furthermore, therapy must be temporarily discontinued before or during procedures involving intravascular iodinated contrast agents and only reinstituted after renal function has been re-evaluated and confirmed as stable. If a dose is missed, the standard procedure is to take the next scheduled dose at the regular time, without doubling the dose.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metfogamma 850

Evidence for Use in Type 2 Diabetes Management

Metfogamma 850, which contains metformin, was studied for its evaluation in Type 2 Diabetes Mellitus in adults. The foundational evidence includes landmark Randomized Controlled Trials (RCTs) and long-term observational follow-up studies. Researchers examined outcomes related to blood glucose control, such as HbA1c and plasma glucose levels, and long-term diabetes complications. Studies described these measurements compared to non-drug interventions. Research into clinical events primarily references findings from specific extensive trials. While the study of glucose biomarkers is included, evidence for cardiovascular outcomes has sometimes shown mixed findings. Data for individuals with more severe kidney impairment remains limited, though regulatory bodies consider estimated glomerular filtration rate ( eGFR) levels.

Research on Preventing Progression to Type 2 Diabetes

Long-term clinical trials have examined high-risk populations (prediabetes) to describe how studies evaluated the progression to a new diagnosis of Type 2 Diabetes. Key trials reported findings related to progression patterns compared to placebo. This pattern was observed to be variable in subgroups defined by higher body mass index ( BMI). The reported patterns of progression were not identical to intensive lifestyle interventions studied in the same patient populations. Limited information is available on whether this intervention prevents major long-term complications in this high-risk population, and findings appear to be inconsistent across studies.

Evidence Evaluated for Polycystic Ovary Syndrome (PCOS)

The research base for Metformin in PCOS consists of various RCTs and systematic reviews. Studies examined women with PCOS, monitoring outcomes related to menstrual cycle regularity, ovulation rates, and androgen biomarkers. Studies reported findings that described patterns related to these outcomes compared to placebo. Certainty remains low for some key long-term outcomes. Research examining live birth rates yielded mixed findings across available trials. Many of these studies have short follow-up durations and modest sample sizes, meaning there is limited information for long-term health outcomes.

Uncertainty and Research Gaps

The long-term evidence largely references findings from the extended follow-up of initial RCTs. Research has explored adults defined by higher body weight, and older adults were observed in some studies, with findings indicating general patterns can still be observed. Despite decades of evidence, some areas are still uncertain. The long-term effects on cardiovascular complications in the prediabetes population are not fully established. Research also continues to examine its use in patients with complex comorbidities.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Metfogamma 850 (FAQ)

Q: How does Metfogamma 850 help regulate blood glucose levels?

According to official information, Metfogamma 850 helps regulate blood glucose through dual action. It suppresses the excessive production of glucose by the liver and also enhances the body's natural sensitivity to insulin in muscle and fat tissues. This dual action is described as assisting the clearance of glucose from the bloodstream.

Q: Is Metfogamma 850 the same as other brands of metformin?

Metfogamma 850 contains the precise active ingredient, Metformin Hydrochloride, which is the same as in other authorized brands of metformin. Differences between products generally relate to the inactive ingredients or the specific tablet design used by the manufacturer.

Q: Can Metfogamma 850 cause hypoglycemia (low blood sugar) when taken alone?

Official safety information indicates that when Metfogamma 850 is used alone (monotherapy), it is not typically associated with causing an episode of low blood sugar (hypoglycemia). The risk is primarily noted when this drug is combined with certain other glucose-lowering medicines.

Q: Is there information about Metfogamma 850 affecting Vitamin B12 levels?

Regulatory documents state that the use of Metfogamma 850 may cause a reduction in serum Vitamin B12 levels. Because of this known effect, official product information mentions that a patient's Vitamin B12 status should be monitored during treatment.

Q: What happens if a dose of Metfogamma 850 is missed?

Regulatory guidance states that if a dose is missed, the next scheduled dose should be taken at the regular time, without doubling the amount taken. This specific instruction prevents excessive accumulation of the drug in the body, which could increase the potential for adverse effects.

Q: Why are people sometimes advised to take Metfogamma 850 with food?

The drug is often prescribed to be taken with meals to improve its gastrointestinal tolerability and reduce the likelihood of common side effects like nausea and diarrhea. Official studies have shown that taking the tablet with food decreases the rate and extent of the drug's absorption.

Q: Does Metfogamma 850 cause weight loss or weight gain?

Weight change is not listed as a primary intended effect of the medication in the official product information. However, clinical studies have described patterns where patients may experience a modest weight reduction or stable weight while on the medication.

Q: Do I need to change my diet or exercise routine while taking Metfogamma 850?

Official sources indicate that the drug is intended to be used alongside appropriate lifestyle adjustments, including diet and exercise. The drug's authorization describes its use as an adjunct (an addition) to proper dietary management and weight reduction.

Q: Is a metallic taste in the mouth a commonly reported side effect?

Yes. A metallic taste in the mouth is listed in official regulatory documents as a commonly reported, but generally mild, side effect. This is one of the gastrointestinal-related issues that may occur, particularly when starting treatment.

Q: Can diuretics (water pills) affect the safety or effectiveness of Metfogamma 850?

Yes, co-administration with diuretics (often called water pills) may affect the safety of the medicine. Official warnings state that diuretics can potentially impair kidney function, which in turn can increase the risk of lactic acidosis when taking Metfogamma 850.

Q: What are the required lab tests mentioned in regulatory documents when taking Metfogamma 850?

Regulatory documents require ongoing safety monitoring through specific lab tests. Renal function, measured by the estimated Glomerular Filtration Rate (eGFR), must be assessed before beginning treatment and at least annually thereafter. Monitoring of Vitamin B12 levels is also mentioned.

Q: Can Metfogamma 850 be used by patients who are not overweight?

Yes. The drug is approved for the treatment of Type 2 Diabetes Mellitus regardless of a patient’s body weight. While some research may highlight its effects in certain weight subgroups, weight is not a requirement for the official indication for use.

Q: What official guidance exists on using Metfogamma 850 if I become severely sick with vomiting or diarrhea?

Official guidance suggests that in cases of severe illness, such as severe vomiting, diarrhea, or fever that leads to dehydration, temporary discontinuation of the drug is generally recommended. This action helps to reduce the risk of developing acute kidney injury and the serious complication of lactic acidosis.

Q: What are the known research findings related to the long-term benefit of Metfogamma 850?

Key long-term studies have demonstrated that the drug is associated with a significantly lower risk of certain diabetes-related outcomes and death over an extended period. These observed benefits are noted to be separate from its primary blood glucose-lowering effects.

Q: Is there evidence concerning the use of Metfogamma 850 in preventing diabetes complications?

Long-term clinical trials have observed patterns that are associated with a reduced incidence of serious complications in specific patient populations. These include a reduction in diabetes-related death, myocardial infarction (heart attack), and all-cause mortality.

Q: What are the known research themes for the active ingredient in Metfogamma 850?

The primary research themes include the evaluation of the drug in Type 2 Diabetes Mellitus management and its potential role in the prevention of progression to Type 2 Diabetes in high-risk populations. Studies have also been conducted on its use in Polycystic Ovary Syndrome (PCOS).

Q: Is the safety classification of Metfogamma 850 for use in pregnancy?

Official documents state that the drug is not recommended during pregnancy. The drug is classified as Category C by the Australian TGA, which indicates that reversible harmful effects on the fetus have been observed or suspected.

Q: Is there any information about Metfogamma 850 passing into breast milk?

Limited published studies report that the active ingredient is present in human milk in low amounts. While the drug is not generally recommended while breastfeeding, the potential effects on the breastfed infant are not fully established in all cases.

Q: Do over-the-counter pain relievers or anti-inflammatories interact with Metfogamma 850?

Yes. The drug's use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a category that includes many common over-the-counter pain relievers, is associated with a potential increase in the risk of lactic acidosis. This risk is due to the NSAIDs' possible effect on kidney function.

Q: Are there specific organ conditions, like liver or kidney issues, that prevent use of Metfogamma 850?

Severe kidney impairment (a low estimated GFR) and hepatic insufficiency (liver disease) are formal contraindications, meaning the drug must not be used. However, use in cases of moderate kidney impairment is conditional and typically requires a lower dose and frequent monitoring.

Advertisements

How should Metfogamma 850 be stored and disposed of?

Storage and Disposal of Metfogamma 850 (Metformin Hydrochloride)


Official Storage Requirements

Metfogamma 850 tablets must be stored at Controlled Room Temperature (CRT), which is 20 C to 25 C (68 F to 77 F). The product must be protected from excessive moisture and high humidity. It is mandatory to keep the medication in its original container and store it out of the sight and reach of children.


Disposal Protocol

Disposal of unused or expired tablets must follow regulatory guidelines. The preferred method is using a community drug take-back program. If this option is unavailable, the tablets must be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed container, and disposed of in the household trash. Do not flush Metfogamma 850 down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metfogamma 850 found in:

A-Z Index: